Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27780878 | 0.90 | CARM1 (0.50) | CXCR3CARM1PRMT6MEN1KMT2A | |
| SCHEMBL3321651 | 0.84 | PKM (0.61) | ACHEBCHEBACE1PKML3MBTL1 | |
| SCHEMBL3323699 | 0.81 | DRD2 (0.62) | CXCR3ACHEPKML3MBTL1MEN1 | |
| SCHEMBL3322725 | 0.79 | MEN1 (0.50) | ACHEBCHEBACE1PKML3MBTL1 | |
| SCHEMBL13361813 | 0.79 | DRD2 (0.53) | CXCR3ACHEPKML3MBTL1MEN1 | |
| SCHEMBL3323191 | 0.78 | DRD2 (0.52) | CXCR3ACHEPKML3MBTL1MEN1 | |
| SCHEMBL27780900 | 0.76 | MEN1 (0.51) | ACHEPKML3MBTL1MEN1KMT2A | |
| SCHEMBL8143331 | 0.74 | OPRM1 (0.57) | CXCR3CARM1PRMT6ACHEBCHE | |
| SCHEMBL3323404 | 0.73 | SIGMAR1 (0.52) | ACHEBCHEBACE1DRD4 | |
| SCHEMBL3321203 | 0.72 | PKM (0.47) | ACHEPKML3MBTL1CHRM4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | claimed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | claimed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8933101-B2 | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A., (ES) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120860-A1 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | GRIN2A, DRD2, GRIN2C | CXCR3 3438/4885CARM1 3707/4885PRMT6 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.